U.S. regulatory update

RNS Number : 6964D

Allergy Therapeutics PLC

28 March 2011

 



Monday 28 March 2011

Allergy Therapeutics plc

("Allergy Therapeutics" or "the Company")

U.S. regulatory update

Allergy Therapeutics plc (AIM: AGY), the fully integrated specialty pharmaceutical company specialising in allergy vaccines is pleased to announce that it met with the U.S. Food and Drug Administration (FDA) for a productive discussion. The FDA has informed the Company of its intention to lift the clinical hold in order to allow the development of MATA-MPL^© products to move forward. The Company expects to receive the formal communication from the FDA in the coming weeks.

Manuel Llobet, Chief Executive of Allergy Therapeutics, said:

"We are very pleased to have received positive feedback from the FDA and look forward to providing more information when the  formal communication is received."

-Ends-

For further information

Allergy Therapeutics	[phone]
Manuel Llobet, Chief Executive Officer
Ian Postlethwaite, Finance Director
www.allergytherapeutics.com
Nomura Code Securities	[phone]
Juliet Thompson/ Clare Terlouw
Financial Dynamics	[phone]
Ben Brewerton/ Susan Quigley

About Pollinex^® Quattro

Pollinex^® Quattro is a four injection therapeutic vaccine which is being developed for the treatment of allergic conditions which offers same season relief in as little as three weeks after treatment. It is a family of specific standardised vaccines representing a potentially extensive franchise for Allergy Therapeutics and is a novel entrant in the multibillion dollar global allergy market. It is currently available in Europe on a named patient basis.

 

END

 

 

MSCDKODNFBKDDNB